Nicole A. McNeer, Ph.D. - Publications

2013 Biomedical Engineering Yale University, New Haven, CT 

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, Shah M, Arora K, Emde AK, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. PMID 30760869 DOI: 10.1038/s41375-019-0402-3  0.6
2015 McNeer NA, Anandalingam K, Fields RJ, Caputo C, Kopic S, Gupta A, Quijano E, Polikoff L, Kong Y, Bahal R, Geibel JP, Glazer PM, Saltzman WM, Egan ME. Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nature Communications. 6: 6952. PMID 25914116 DOI: 10.1038/ncomms7952  0.84
2015 Fields RJ, Quijano E, McNeer NA, Caputo C, Bahal R, Anandalingam K, Egan ME, Glazer PM, Saltzman WM. Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung. Advanced Healthcare Materials. 4: 361-6. PMID 25156908 DOI: 10.1002/adhm.201400355  0.84
2014 Bahal R, Quijano E, McNeer NA, Liu Y, Bhunia DC, Lopez-Giraldez F, Fields RJ, Saltzman WM, Ly DH, Glazer PM. Single-stranded γPNAs for in vivo site-specific genome editing via Watson-Crick recognition. Current Gene Therapy. 14: 331-42. PMID 25174576  0.84
2014 Ricciardi AS, McNeer NA, Anandalingam KK, Saltzman WM, Glazer PM. Targeted genome modification via triple helix formation. Methods in Molecular Biology (Clifton, N.J.). 1176: 89-106. PMID 25030921 DOI: 10.1007/978-1-4939-0992-6_8  0.84
2013 Schleifman EB, McNeer NA, Jackson A, Yamtich J, Brehm MA, Shultz LD, Greiner DL, Kumar P, Saltzman WM, Glazer PM. Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. Molecular Therapy. Nucleic Acids. 2: e135. PMID 24253260 DOI: 10.1038/mtna.2013.59  0.84
2013 Bahal R, McNeer NA, Ly DH, Saltzman WM, Glazer PM. Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5. Artificial Dna, Pna & Xna. 4: 49-57. PMID 23954968 DOI: 10.4161/adna.25628  0.84
2013 McNeer NA, Schleifman EB, Cuthbert A, Brehm M, Jackson A, Cheng C, Anandalingam K, Kumar P, Shultz LD, Greiner DL, Mark Saltzman W, Glazer PM. Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Therapy. 20: 658-69. PMID 23076379 DOI: 10.1038/gt.2012.82  0.84
2011 McNeer NA, Schleifman EB, Glazer PM, Saltzman WM. Polymer delivery systems for site-specific genome editing. Journal of Controlled Release : Official Journal of the Controlled Release Society. 155: 312-6. PMID 21620910 DOI: 10.1016/j.jconrel.2011.05.011  0.84
2011 McNeer NA, Chin JY, Schleifman EB, Fields RJ, Glazer PM, Saltzman WM. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 172-80. PMID 20859257 DOI: 10.1038/mt.2010.200  0.84
Show low-probability matches.